The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

Mesigyna     [(8R,9S,10R,13S,14S,17S)-17- ethynyl-13...

Synonyms: Hrp 102, KST-1A0265, AC1L3GZE, AR-1A0622, AC1Q5X69
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Hrp 102

  • Based on the results from toxicity testing, there were no objections to the long-term therapeutic use of Mesigyna for hormonal contraception [1].
  • The duration of bleeding days as well as dysmenorrhea were less with Mesigyna [2].

High impact information on Hrp 102


Chemical compound and disease context of Hrp 102


Biological context of Hrp 102

  • After a single injection of Cyclofem and Mesigyna, both formulations showed equal contraceptive effect with inhibition of follicle maturation for some 30 days and ovulation, corpus luteum formation for some 60 days [4].
  • In order to attain predictable menstrual cycle control as well as high efficacy with a 30-day injection schedule, two improved once-a-month injectable formulations, Cyclofem and Mesigyna, were developed [4].

Associations of Hrp 102 with other chemical compounds

  • Thereafter, 50% of Mesigyna users had precisely 3 bleeding/spotting episodes every 90 days, 50% of Cyclofem users had 2-3 and 50% of Injectable No. 1 users had 3-4 episodes every 90 days [5].

Analytical, diagnostic and therapeutic context of Hrp 102

  • The objective of this study was to determine the effects of a once-monthly injectable contraceptive (Mesigyna) on menstrual pattern, lipoproteins, and coagulation parameters [6].
  • The incidence of bleeding anomalies was higher in the Mesigyna group, with a discontinuation rate for these reasons of 20% versus 4% for IUD (p <0.05) [2].


WikiGenes - Universities